MedPath

Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.

Recruiting
Conditions
Peripartum Cardiomyopathy
Interventions
Diagnostic Test: Molecular and genetic screening
Registration Number
NCT05878041
Lead Sponsor
Federico II University
Brief Summary

Peripartum cardiomyopathy (PPCM) is a rare, severe and potentially life-threatening disorder of largely unknown etiology and pathophysiology, with unexplained geographical differences and heterogeneous presentation. Investigators hypothesize that a network-based multidisciplinary strategy integrating clinical and molecular phenotyping of PPCM patients might anticipate diagnosis, optimize treatments, and identify novel mechanisms to achieve the unmet goal of personalized medicine.

Detailed Description

Specific aims of this study are: a) to create a multicenter pilot registry of PPCM in different areas in Italy to assess incidence and prevalence of this rare disease, associated comorbidities and risk factors. b) to deeply characterize identified PPCM patients through clinical, imaging, genetic, biochemical, and molecular phenotyping. c) to gain novel mechanistic information on PPCM by performing deep clinical and molecular phenotyping in available biobanks samples of patients with PPCM and healthy controls.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Healthy pregnant volunteersMolecular and genetic screeningHealthy pregnant women
Peripartum cardiomyopathyMolecular and genetic screeningDiagnosis of Peripartum cardiomyopathy (PPCM) will be defined according to the ESC guidelines as: (i) the development of the disease in the last month of pregnancy or within 5 months of delivery; (i) absence of an identifiable cause of heart failure; (iii) absence of recognizable heart disease before the last month of pregnancy; (iv) left ventricle systolic dysfunction demonstrated by classical echocardiographic criteria.
Primary Outcome Measures
NameTimeMethod
Development of significant cardiac arrhythmias0-6 months

New onset sustained supraventricular or ventricular arrhythmias or conduction blocks during the follow-up period

Death or hospitalization due to heart failure0-6 months

Death or hospitalization due to heart failure during the follow-up period

Secondary Outcome Measures
NameTimeMethod
Left ventricular dysfunction0-6 months

Left ventricular % ejection fraction during the follow-up period

Trial Locations

Locations (1)

Federico II University Hospital

🇮🇹

Naples, Italy

© Copyright 2025. All Rights Reserved by MedPath